文献速递免疫规划卫生政策与健康促进

法国HPV疫苗犹豫决定因素调查问卷的设计与内容验证:反应性德尔菲研究

Design and content validation of a survey questionnaire assessing the determinants of human papillomavirus (HPV) vaccine hesitancy in France: A reactive Delphi study.
PubMed 文献 · Vaccine · 2020-07-25

本研究旨在开发并初步验证法国HPV疫苗犹豫决定因素调查问卷(FSQD-HPVH)。最终问卷包含57个条目,内容效度良好。

要点

  • 基于WHO SAGE疫苗犹豫模型开发法国HPV疫苗犹豫调查问卷。
  • 问卷将用于评估HPV疫苗犹豫决定因素,为提升接种率提供依据。

核心结论

  • 成功开发了内容效度良好的法国HPV疫苗犹豫决定因素调查问卷(FSQD-HPVH),最终包含57个条目。

主要发现

  • 第一轮评估83个条目,其中35个(42%)CVR≥0.6被直接接受。
  • 第二轮评估66个条目(第一轮未达共识条目及新提议条目),其中22个(33%)达到CVR≥0.6共识。
  • 最终FSQD-HPVH版本包含57个条目。

关键数值与推荐

  • 条目评分采用3点Likert量表:1=必要,2=有用但非必要,3=不必要。
  • 共识阈值:Lawshe内容效度比(CVR)≥0.6。

临床怎么用

  • 该问卷可用于评估法国HPV疫苗犹豫的决定因素,为制定循证干预策略、提升HPV疫苗接种率提供工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study aimed to develop and undertake a preliminary validation of a French Survey Questionnaire for the Determinants of HPV Vaccine Hesitancy (FSQD-HPVH). METHODS: We undertook an electronic-based Delphi consultation among a panel of Francophone experts in two rounds. Round 1 consisted of the assessment of a structured questionnaire comprising of three parts ((i) Contextual influences, (ii) Individual and group influences, and (iii) Vaccine/vaccination-specific issues), in line with the WHO Strategic Advisory Group of Experts (SAGE) Vaccine Hesitancy (VH) Model of Determinants. Items included in this questionnaire were based on a literature review. Definitions of the factors included in the SAGE model were provided in the questionnaire. The panel of experts was asked to score each item using a 3-point Likert scale, in which 1 meant "Essential", 2 "Useful but not essential", and 3 "Not necessary". The panel was also invited to comment on the clarity/comprehension of the questions and suggest reformulations/additional items. Lawshe's Content Validity Ratio (CVR) was computed to assess the level of consensus for each statement. Only items upon which agreement was not reached in Round 1 (CVR < 0.6) and newly proposed items were submitted for evaluation in Round 2, using the same procedure. RESULTS: Fifteen experts completed the two rounds. Of 83 items evaluated in Round 1, 35 (42%) had a CVR ≥ 0.6 and were accepted without modification. In Round 2, 66 items were submitted to the same panel and consensus was reached for 22 (33%) items using the threshold of 0.6. The final FSQD-HPVH version includes 57 items. CONCLUSION: This study developed a survey instrument for the evaluation of HPV VH in France with good content validity. It will be used to assess the determinants of HPV VH, the first step towards an evidence-based approach to improving HPV vaccination rates in France.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dib F, Mayaud P, Launay O, et al. Design and content validation of a survey questionnaire assessing the determinants of human papillomavirus (HPV) vaccine hesitancy in France: A reactive Delphi study. Vaccine. 2020. PMID: 32723510. doi:10.1016/j.vaccine.2020.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。